Seeing Is Believing
Currently out of the existing stock ratings of Thomas Wei, 3 are a SELL (9.09%), 3 are a HOLD (9.09%), 27 are a BUY (81.82%).
Analyst Thomas Wei works with a stock forecast success ratio of 83.33% fulfilled within 586.5 days on average. Previously, Thomas Wei worked at JEFFERIES.
Thomas Wei’s has documented 68 price targets and ratings displayed on 10 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on STML, Stemline Therapeutics at 22-Apr-2015.
Analyst best performing recommendations are on ACAD (ACADIA PHARMACEUTICALS).
The best stock recommendation documented was for ACAD (ACADIA PHARMACEUTICALS) at 5/6/2013. The price target of $18 was fulfilled within 35 days with a profit of $5.82 (47.78%) receiving and performance score of 13.65.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Sell
5 months 3 days ago
1/3 (33.33%)
$-0.04 (-0.99%)
300
Hold
1
$-0.07 (-6.54%)
5
5 months 29 days ago
4/21 (19.05%)
$0.29 (40.85%)
32
Sell
1
$-0.07 (-6.54%)
3.5
9 months 4 days ago
8/11 (72.73%)
$-0.08 (-7.41%)
55
Hold
1.25
$0.18 (16.82%)
2
9 months 4 days ago
2/5 (40%)
$0.17 (15.74%)
215
Buy
10
1 years 10 months 1 days ago
13/47 (27.66%)
$6.81 (213.48%)
194
What Year was the first public recommendation made by Thomas Wei?